Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;26(9):1276-1277.
doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.

Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19

S Gevers  1 , M S G Kwa  2 , E Wijnans  2 , C van Nieuwkoop  3
Affiliations

Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19

S Gevers et al. Clin Microbiol Infect. 2020 Sep.
No abstract available

PubMed Disclaimer

References

    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed
    1. Goyal P., Choi J.J., Pinheiro L.C., Schenck E.J., Chen R., Jabri A. Clinical characteristics of Covid-19 in New York city. N Engl J Med. 2020 doi: 10.1056/NEJMc2010419. Online ahead of print. - DOI - PMC - PubMed
    1. Plantone D., Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Invest. 2018;38:653–671. - PubMed
    1. Taylor W.R., White N.J. Antimalarial drug toxicity: a review. Drug Saf. 2004;27:25–61. - PubMed
    1. VigiAccessTM All data contained in VigiAccessTM is sourced from VigiBase®, the WHO's global database for ADRs. http://www.vigiaccess.org maintained by the Uppsala Monitoring Centre.

MeSH terms

LinkOut - more resources